Actividad Investigadora
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
Fecha de publicación:
Fecha Ahead of Print:
Autores de IDIVAL
Autores ajenos al IDIVAL
- Noureddin M
- Truong E
- Mayo R
- Martínez-Arranz I
- Mincholé I
- Banales JM
- Arrese M
- Cusi K
- Bruha R
- Romero-Gómez M
- Aller R
- Ampuero J
- Calleja JL
- Ibañez-Samaniego L
- Aspichueta P
- Marín-Duce A
- Kushner T
- Ortiz P
- Harrison SA
- Anstee QM
- Mato JM
- Sanyal AJ
Unidades
Abstract
Background: Early identification of those with NAFLD activity score >= 4 and significant fibrosis (>= F2) or at-risk metabolic dysfunction-associated steatohepatitis (MASH) is a priority as these patients are at increased risk for disease progression and may benefit from therapies. We developed and validated a highly specific metabolomics-driven score to identify at-risk MASH. Methods: We included derivation (n = 790) and validation (n = 565) cohorts from international tertiary centers. Patients underwent laboratory assessment and liver biopsy for metabolic dysfunction-associated steatotic liver disease. Based on 12 lipids, body mass index, aspartate aminotransferase, and alanine aminotransferase, the MASEF score was developed to identify at-risk MASH and compared to the FibroScan-AST (FAST) score. We further compared the performance of a FIB-4 + MASEF algorithm to that of FIB-4 + liver stiffness measurements (LSM) by vibration-controlled transient elastography (VCTE). Results: The diagnostic performance of the MASEF score showed an area under the receiver-operating characteristic curve, sensitivity, specificity, and positive and negative predictive values of 0.76 (95% CI 0.72-0.79), 0.69, 0.74, 0.53, and 0.85 in the derivation cohort, and 0.79 (95% CI 0.75-0.83), 0.78, 0.65, 0.48, and 0.88 in the validation cohort, while FibroScan-AST performance in the validation cohort was 0.74 (95% CI 0.68-0.79; p = 0.064), 0.58, 0.79, 0.67, and 0.73, respectively. FIB-4 + MASEF showed similar overall performance compared with FIB-4 + LSM by VCTE (p = 0.69) to identify at-risk MASH. Conclusion: MASEF is a promising diagnostic tool for the assessment of at-risk MASH. It could be used alternatively to LSM by VCTE in the algorithm that is currently recommended by several guidance publications.
Datos de la publicación
- ISSN/ISSNe:
- 0270-9139, 1527-3350
- Tipo:
- Article
- Páginas:
- 135-148
- PubMed:
- 37505221
HEPATOLOGY LIPPINCOTT WILLIAMS & WILKINS
Citas Recibidas en Web of Science: 52
Documentos
- No hay documentos
Filiaciones
Campos de Estudio
Cita
Noureddin M, Truong E, Mayo R, Martínez I, Mincholé I, Banales JM, Arrese M, Cusi K, Arias MT, Bruha R, Romero M, Iruzubieta P, Aller R, Ampuero J, Calleja JL, Ibañez L, Aspichueta P, Marín A, Kushner T, Ortiz P, Harrison SA, Anstee QM, Crespo J, Mato JM, Sanyal AJ. Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF). Hepatology. 2024. 79. (1):p. 135-148. IF:13,000. (1).
